[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Ethiopia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":752},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,54,0,25,[9,48,79,109,137,165,193,220,259,285,315,340,371,421,449,486,514,545,570,592,622,651,675,704,730],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100642705","holistic-approach-supporting-the-uptake-of-innovative-diagnostic-technologies-for-respiratory-infections-100642705",false,"NCT07651865","Holistic Approach Supporting the Uptake of Innovative Diagnostic Technologies for Respiratory Infections","Clinical Validation of Novel Microfluidic and Lateral Flow-based Technologies for the Detection of Lower and Upper Respiratory Tract Infections - HOLICARE Trial","HOLICARE","Inclusion Criteria:\n\n* Age ≥ 6 months\n* Presentation with suspected respiratory tract infection and at least two of the following symptoms:\n* Fever (axillary temperature ≥37.5°C) or history of fever\n* New acute cough episode\n* Shortness of breath\n* Tachypnoea (fast breathing)\n* Loss of smell and\u002For taste\n* Ability to provide written informed consent (or assent with parent\u002Fguardian consent for minors)\n* For infants (≤1 year), both fever and new acute cough must be present at screening\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent\u002Fassent\n* Refusal to provide study samples\n* Severe chronic medical conditions or mental incapacity that, in the opinion of the clinician, would interfere with study participation\n* Hospitalisation within the previous 2 weeks for reasons unrelated to the current respiratory symptoms\n* Acute injury, trauma, or poisoning interfering with participation\n* Chronic cough lasting \\>2 weeks, unless tuberculosis is suspected in the LRTI cohort\n* Antibiotic use within the previous 2 weeks for participants enrolled in the LRTI cohort (Sub-study 2) only","ALL","6 Months",{"count":21,"type":22},2160,"ESTIMATED","OBSERVATIONAL","This observational diagnostic validation study aims to evaluate the clinical performance of novel lateral flow and microfluidic-based technologies for the detection of upper and lower respiratory tract infections in children and adults presenting with respiratory symptoms in Uganda, Ethiopia, and Senegal. The main questions it aims to answer are:\n\n1. whether the novel multiplex lateral flow tests and point-of-care microfluidic platform demonstrate sufficient sensitivity and specificity for detecting respiratory pathogens compared with standard laboratory reference methods, and\n2. whether these technologies are feasible and usable in low-resource clinical settings.\n\nParticipants presenting with suspected respiratory tract infections as part of routine clinical care will provide respiratory and blood samples for diagnostic testing and biobanking, and demographic and clinical information will be collected during a single study visit. Some adult participants and community stakeholders will also complete surveys or interviews regarding the acceptability of biobanking and diagnostic implementation.",[26,27],"Upper Respiratory Infection","Lower Resp Tract Infection",[29,30,31,32,33,34],"Point of Care","POC","Later Flow Test (LFT)","Global Health","Rapid diagnostic","Microfluidics","RECRUITING","2026-06-24",{"date":38,"type":39},"2026-06-29","ACTUAL",{"date":41,"type":39},"2025-04-07",{"date":43,"type":22},"2026-08-31",{"name":45,"class":46},"Karolinska Institutet","OTHER",3,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100644089","the-effects-of-prenatal-health-education-on-birth-preparedness-and-complication-readiness-among-pregnant-women-100644089","NCT07666945","The Effects Of Prenatal Health Education On Birth Preparedness And Complication Readiness Among Pregnant Women","The Effects Of Prenatal Health Education On Birthpreparedness And Complication Readiness Among Pregnant Women In Districts Of West Shewa Zone: A Step-Wedged Randomized Controlled Trial","Inclusion Criteria:\n\n* Pregnant women who are in the first trimester of their pregnancy (up to 16 weeks' gestation) and\n* Pregnant women who have lived in the study area for more than six months will be included.\n\nExclusion criteria\n\n* Pregnant women with serious illnesses or those who intend to move during the intervention's execution\n* Severe conditions requiring intensive hospital follow-up.\n* Pregnant women who have previously taken part in a similar study elsewhere will not be allowed to join.","FEMALE","18 Years",{"count":58,"type":22},576,"INTERVENTIONAL",[61],"NA","Study setting: The study will be conducted from May 1 to November 2026 in the West Shewa Zone.\n\nObjectives: To measure the effect of health education on birth preparedness and complication readiness practice among pregnant women in the districts of the West Shewa Zone in 2026 (Stepped Wedge Randomized Controlled Trial) Null hypothesis (H₀): There will be no difference in the proportion of birth preparedness and complication readiness among pregnant women between intervention and control periods.\n\nAlternative Hypothesis (Ha): Health education intervention on BPCR will result in a significant increase in the proportion of well-prepared pregnant women in the intervention periods across all study sites.\n\nThe study population will consist of randomly selected pregnant women in selected public health centers in Districts of west shewa zone.\n\nThe west shewa zone districts were selected by simple random sampling methods .Ejere, Ejersa Lefo and Holota districts were selected using simple random sampling .Then Five health centers namely Yaya , Olankomi, Gorba ,Ejere and Gilgel kuyu health centers from three districts of west shewa zone were selected.\n\nWill be then randomized to time of crossover (step) using computer-generated sequences. Because of this, the study design involves a sequential rollout where all groups eventually receive the health education intervention aimed at evaluating birth preparedness and complication readiness changes. At the beginning, the five clusters were identified by simple random sampling. Sequential allocation or randomly assigning each cluster to a specific wedge or starting point will be conducted. At the baseline all clusters begin in the control phase. During the steps (every month to six months) one or more clusters cross over to the intervention phase (implementing BPCR education). During the end phases, all clusters are in the intervention group. The study involves cohort sampling; the same pregnant women are followed through the entire study for six months. All eligible pregnant women attending antenatal care during defined periods in each cluster will eventually receive health education.",[64],"Birth Preparedness and Complication Readiness",[66,67,68,69],"step-wedged","health education","birth preparedness","complication readiness","2026-06-19",{"date":36,"type":39},{"date":73,"type":39},"2026-05-01",{"date":75,"type":22},"2026-10-30",{"name":77,"class":46},"Bule Hora University",1,{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":86,"targetDuration":88,"studyType":23,"phases":4,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":78},"100641722","polyvalent-antivenom-premium-panaf-for-snakebite-envenoming-in-ethiopia-100641722","NCT07659002","Polyvalent Antivenom (Premium-PANAF) for Snakebite Envenoming in Ethiopia","A Prospective Cohort Study of Polyvalent Antivenom (Premium-PANAF) for Snakebite Envenoming in Ethiopia","Inclusion criteria\n\n* Snakebite envenoming patients who receive Premium-PANAF antivenom\n* Patients who have given written informed consent .\n\nExclusion criteria\n\n* Snakebite envenoming patients who do not receive Premium-PANAF antivenom\n* Patients referred from other centres who already received other antivenom treatment\n* Patients who are unable or unwilling to give informed consent",{"count":87,"type":22},600,"42 Days","Snakebite Envenomation is recognised as a Neglected Tropical Diseases with high lethality in Sub-Saharan Africa. The current syndromic treatment approach is also fraught by supply pipeline constraints and need for cold-chain, thus negatively impacting outcomes in resource limited settings.\n\nDespite the lack of clinical outcome data from studies in humans, after a comprehensive risk-benefit assessment, the World Health Organisation (WHO), in May 2023, recommended the use of Premium-PANAF polyvalent snake antivenom that is lyophilised, and therefore does not require cold-chain conditions. Médecins Sans Frontières (MSF) also updated its treatment protocol with Premium PANAF being standard of care since June 2025 at Abdurafi (Midre Genet) Health Centre in north west Ethiopia.\n\nReal-world effectiveness by means of Phase IV post marketing studies or pharmacovigilance programmes in countries where it has recently been rolled out is not yet available. This prospective observational cohort study, with a capped sample size of 600 patients, would thus provide much needed evidence on the safety and effectiveness of Premium-PANAF in resource limited settings to help inform national and international treatment guidelines.",[91],"Snake Envenomation",[93,94,95,96,97,98,99],"prospective observational cohort","Ethiopia","treatment","safety","effectiveness","antivenom","snakebite","2026-06-15",{"date":102,"type":39},"2026-06-22",{"date":104,"type":39},"2025-06-02",{"date":106,"type":22},"2026-09-01",{"name":108,"class":46},"Medecins Sans Frontieres, Netherlands",{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":59,"phases":120,"briefSummary":121,"conditions":122,"keywords":125,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":78},"100642287","mobile-based-telemedicine-and-health-related-quality-of-life-among-patients-with-chronic-heart-failure-mobile-hf-100642287","NCT07650474","Mobile-Based Telemedicine and Health-Related Quality of Life Among Patients With Chronic Heart Failure (MOBILE-HF)","Effectiveness of Mobile-Based Telemedicine on Health-Related Quality of Life Among Patients With Chronic Heart Failure: Protocol for a Quasi-Experimental Study","MOBILE-HF","Inclusion Criteria:\n\n* Adults aged 18-65 years who will be diagnosed with CHF (NYHA class II⁃III)\n* Patients with reduced left ventricular ejection fraction LVEF ≤ 40%\n* Patient who will have access to a mobile phone and will be able to use it\n* Patients who will be able to communicate in Amharic, Oromic, or English\n* Patients who will provide written informed consent\n* Patients who will be diagnosed with HF lasting ≥ 6 months, to be confirmed by echocardiography and clinical assessment\n* Patients with no contraindications for mild to moderate physical activity\n\nExclusion Criteria:\n\n* Patients with NYHA class IV or who will require intensive care at enrollment\n* Patients with other severe medical conditions (e.g., end-stage renal disease, \\& end stage liver disease)\n* Patients with severe cognitive impairment or psychiatric illness that will interfere with participation\n* Patients already enrolled in another telemedicine or intervention study\n* Pregnant and lactating women","65 Years",{"count":119,"type":22},72,[61],"Chronic heart failure (CHF) is a long-term condition in which the heart is unable to pump blood effectively. It can cause symptoms such as shortness of breath, fatigue, swelling in the legs, and reduced ability to perform daily activities. These problems often reduce a patient's quality of life and may lead to frequent hospital visits.\n\nThis study will assess whether a mobile-based telemedicine program can improve the health-related quality of life of patients with chronic heart failure in Ethiopia.\n\nIn this study, 70 adult patients with chronic heart failure will be included. They will be divided into two groups: 35 patients will receive routine care plus mobile-based telemedicine support, and 35 patients will receive routine care only.\n\nThe mobile-based telemedicine program will include health education, medication reminders, lifestyle advice, and follow-up support delivered through phone calls and text messages over an 8-week period.\n\nPatients' quality of life will be measured at the beginning of the study and again after 8 weeks using a standard questionnaire called the Minnesota Living with Heart Failure Questionnaire (MLHFQ).\n\nThe main goal of the study is to determine whether mobile-based telemedicine improves quality of life compared with routine care alone. The study may also help improve self-care behaviors, medication adherence, and symptom control among patients with heart failure.\n\nThe findings may provide evidence to support the use of mobile health technologies as a simple and scalable approach to improve heart failure care in Ethiopia.",[123,124],"Chronic Heart Failure","Health Related Quality of Life",[126,127,128],"Health-related quality of life","Mobile-based telemedicine","Chronic heart failure",{"date":130,"type":39},"2026-06-17",{"date":132,"type":39},"2026-03-02",{"date":134,"type":22},"2026-08-21",{"name":136,"class":46},"Select College",{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":144,"targetDuration":146,"studyType":23,"phases":4,"briefSummary":147,"conditions":148,"keywords":152,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":162,"leadSponsor":164,"locationsCount":78},"100642614","infection-prevention-for-bellwether-surgery-in-ethiopia-100642614","NCT07647796","Infection Prevention for \"Bellwether\" Surgery in Ethiopia","Infection Prevention for \"Bellwether\" Surgery in Ethiopia: Efficacy, Antimicrobial Resistance, Long-term Patient Outcomes, and Cost-effectiveness","Inclusion Criteria:\n\n* Emergency Caesarean section.\n* Open tibia\u002Ffemur fractures.\n* Treated at participating Ethiopian hospitals.\n\nExclusion Criteria:\n\n* Elective or non-bellwether surgeries.\n* Inability to provide informed consent.\n* Lost to follow-up for 24-month assessment.",{"count":145,"type":22},1000,"24 Months","The study examines surgical site infections and antimicrobial resistance following life-saving surgeries like C-sections and leg fracture repairs in Ethiopia. It does not include healthy volunteers because it specifically focuses on patients who require these urgent operations due to medical necessity. Eligible participants are those undergoing these specific procedures at Tikur Anbessa Specialized Hospital or other participating public hospitals. While the birth-related portion is for females, the trauma portion includes both men and women, generally of reproductive or working age with no upper age limit. People are excluded if they are having elective surgeries, cannot provide consent, or cannot be reached for the two-year follow-up period. The researchers use a mixed intervention based on the \"Clean Cut\" safety bundle, which includes staff training, surgical checklists, and regular audits. The main goals are to measure infection rates within 30 days of surgery and track how well patients can function in their daily lives using the WHODAS scale up to 24 months later.",[149,150,151],"Ceserean Section","Lower Limb Fractures","Surgical Site Infection (SSI)",[153,154,94,155,156,157],"Surgical Site Infections","Global Surgery","Multidrug resistance","Antimicrobial resistance","Subsahara Africa","NOT_YET_RECRUITING","2026-06-09",{"date":100,"type":39},{"date":106,"type":22},{"date":163,"type":22},"2030-08-01",{"name":45,"class":46},{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":18,"minAge":173,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":59,"phases":177,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":78},"100573443","feasibility-of-integrating-thermotherapy-for-treatment-of-cutaneous-leishmaniasis-in-primary-health-care-setup-100573443","NCT06746350","Feasibility of Integrating Thermotherapy for Treatment of Cutaneous Leishmaniasis in Primary Health Care Setup","Feasibility of Integrating Thermotherapy (TT) for Treatment of Cutaneous Leishmaniasis Into the Primary Healthcare Facilities in East Gurage Zone, Ethiopia","TTCL","Inclusion Criteria:\n\n* Males and females aged ≥12 and ≤60 years old.\n* Patient has a lesion that satisfies the following criteria:\n\n  * Lesion size \\\u003C or = 4 cm (longest diameter).\n  * Not located adjacent to ear, nose, eyes, lips, or close to mucosal membranes.\n  * Patient with \\\u003C or = 4 CL lesions\n* Patient able to give written informed consent.\n\nExclusion Criteria:\n\n* Any condition that prevents the patient from following the study treatment and\u002For the follow-up","12 Years","60 Years",{"count":176,"type":22},103,[61],"This study will look at how feasible it is to use thermotherapy (TT) as a treatment for skin(cutaneous) leishmaniasis (CL) in health centers in the Sodo and South Sodo districts, Ethiopia. The main questions the investigators want to answer are:\n\n* Is it practical, acceptable, and suitable to use thermotherapy for treating skin leishmaniasis in these health centers?\n* How effective is thermotherapy in treating skin leishmaniasis in this setting?\n\nHealth centers that do not offer thermotherapy will be used as a comparison group. Patients with CL in these areas will be monitored for up to 3 months before being sent to centers that provide thermotherapy.\n\nParticipants will be checked at a nearby health center to see if they meet the criteria for the study and then will be recruited. Patients with skin lesions will receive thermotherapy using the ThermoMed device, which heats the area to 50°C for 30 seconds. Their progress will be checked every 4 weeks until day 90. Depending on how well they respond, thermotherapy may be repeated at 4 or 8 weeks.",[180],"Cutaneous Leishmaniasis",[180,182,183,184],"Sodo","Thermotherapy","ThermoMed",{"date":186,"type":39},"2026-06-11",{"date":188,"type":39},"2025-04-24",{"date":190,"type":22},"2027-05-25",{"name":192,"class":46},"Armauer Hansen Research Institute, Ethiopia",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":59,"phases":201,"briefSummary":202,"conditions":203,"keywords":206,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":78},"100586648","screening-and-brief-intervention-of-post-war-alcohol-consumption-in-public-hospital-outpatients-100586648","NCT06918106","Screening and Brief-Intervention of Post-war Alcohol Consumption in Public Hospital Outpatients","Inclusion Criteria:\n\n* All gender (Female \\& Male patients)\n* Outpatients aged 18 years and above\n* Outpatients with no serious medical or mental illnesses\n* Outpatients who will be identified to have AUDIT score of 8-19\n\nExclusion Criteria:\n\n* Age less than 18 years\n* Outpatients with serious medical or mental illnesses\n* Outpatients with AUDIT score of less than 7 and above 20",{"count":200,"type":22},262,[61],"Background:\n\nHigh prevalence of alcohol-consumption among conflict-affected population has been reported in some low-and-middle income countries. However, studies that assess the effectiveness of screening and brief-intervention (SBI) in the reduction of unhealthy alcohol consumptions among conflict-affected hospital outpatients in Tigray are insufficient.\n\nObjective:\n\nThis study aims to test the effectiveness of Screening and Brief-Intervention (SBI) in the reduction of unhealthy alcohol consumptions among conflict-affected hospital outpatients in Tigray.\n\nMethod:\n\nAbout 1260 outpatients will be screened for alcohol consumption using Alcohol Use Disorder Identification Test (AUDIT). Those who will have \"8-19\" scores in the AUDIT will be allocated to \"Intervention\" and \"Control\" groups using block randomization and they will be followed at 6 and 12 months of follow - up. The Intervention group will receive simple advice, brief-counseling and 6-and 12-months follow-up screening of alcohol consumptions. However, outpatients in control group will only receive 6- and 12-months follow-up screening of alcohol consumptions. Data will be entered to and will be analyzed using SPSS V 26. Means, standard deviations and percentages will be used for descriptive statistics. Bivariate and multivariate logistic regression, at 95% of confidence interval and p-value of \\\u003C0.05, will be used to identify correlates of alcohol consumption. Independent sample t-test and Mann-Whitney U test will be used to compare AUDIT mean scores of normally and none-normally distributed continuous variables between intervention and control groups respectively.",[204,205],"Effectiveness of Screening and Brief-Intervention","Unhealthy Alcohol Use",[207,208,209,210],"Post-war alcohol use","Screening and Brief-intervention","Harmful alcohol use","Hazardous alcohol use","2026-06-05",{"date":213,"type":39},"2026-06-08",{"date":215,"type":39},"2025-04-03",{"date":217,"type":22},"2026-07-10",{"name":219,"class":46},"Aksum University",{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":228,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":59,"phases":231,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":258},"100626952","enabling-environments-for-non-communicable-disease-risk-reduction-in-ethiopia-100626952","NCT07442318","Enabling Environments for Non-communicable Disease Risk Reduction in Ethiopia","Enhancing Non-Communicable Disease Prevention Among Pregnant Women Through Healthy Lifestyle Promotion in Four Urban Sites in Ethiopia: A Cluster Randomized Controlled Trial in Primary Health Care Facilities","ENABLE","Inclusion Criteria:\n\n* Pregnant women aged 18 years or older\n* Gestational age ≤20 weeks at the time of enrollment\n* Residing in one of the four study cities (Addis Ababa, Adama, Harar, or Jimma)\n* Attending their first antenatal care visit at one of the participating public health facilities\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Pregnant women identified as high risk at enrollment, including those with pre-existing medical conditions, or other conditions requiring specialized care and who cannot continue receiving standard routine ANC.",true,{"count":230,"type":22},1268,[61],"The ENABLE study focuses on pregnant women attending routine antenatal care (ANC) in urban primary health care facilities in four Ethiopian cities. Many women in this setting face increased health risks due to unhealthy diets, low physical activity, and exposure to air pollution which can affect both maternal and newborn health and increase the risk of non-communicable diseases (NCDs) later in life.\n\nIn this study, pregnant women in intervention health centers receive structured, tailored counseling as part of their regular ANC visits. This counseling supports healthier eating, physical activity and reduced exposure to air pollution. Health care providers, including health workers in health centers and Urban Health Extension Professionals (UHEPs), are trained to deliver this counseling supported by a digital ANC eRegistry for clinical decision-making, which enhances adherence to national guidelines, and strengthens the quality of care. Facilitators further strengthen the intervention's implementation by ensuring fidelity to counseling protocols and by adapting content to the Ethiopian urban health system context.\n\nThe study hypothesis is that integrating lifestyle counseling into routine ANC will improve maternal health behaviors and pregnancy outcomes, and reduce NCD risk among pregnant women, compared with standard routine ANC alone.\n\nBy embedding NCD prevention within routine maternal health services, the ENABLE study aims to strengthen the role of ANC as a platform for early prevention and long-term health benefits for women and their children.",[234],"Non-communicable Diseases (NCD)",[236,237,238,239,240,241,242,243,244,245,246,247],"Antenatal care","Pregnancy","Primary Health Care","Behavioral Counseling","Digital Health","Chronic Disease Risk Factors","Health Promotion","Dietary Behavior","Physical Activity","Air Pollution","Health Services Research","Clinical Decision Support Systems","2026-05-27",{"date":250,"type":39},"2026-05-28",{"date":252,"type":39},"2026-05-11",{"date":254,"type":22},"2027-05",{"name":256,"class":257},"Norwegian Institute of Public Health","OTHER_GOV",4,{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":59,"phases":267,"briefSummary":268,"conditions":269,"keywords":273,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":47},"100634523","evaluation-of-7-day-vs-1-day-packaging-of-small-quantity-lipid-based-nutrition-supplementation-sq-lns-100634523","NCT07540793","Evaluation of 7-day vs 1-day Packaging of Small Quantity Lipid-based Nutrition Supplementation (SQ-LNS)","Inclusion Criteria (must meet all):\n\n* Written informed consent from head of household\n* Household within the study area\n* Available for the full 8-week study period\n* 1 child aged 6-22 months in the household at time of enrollment\n* Child has MUAC ≥ 12.5cm\n* Child does not have any clinical complications requiring inpatient treatment or referral to the health post, according to Ethiopian malnutrition treatment guidelines\\*\\*\n* Child is not allergic to peanuts, milk, or soy\n* Household does not have multiple children within the eligible age range\n\nExclusion Criteria (any excludes):\n\n* Head of household declines to sign written informed consent\n* Household is outside of the study area\n* Not available for the full 8-week study period\n* House has either multiple children aged 6-22 months in the household at time of enrollment, or 0 children aged 6-22 months at time of enrollment\n* Child has MUAC \\\u003C 12.5cm\n* Child has any clinical complications requiring inpatient treatment or referral to the health post, according to Ethiopian malnutrition treatment guidelines\n* Child is allergic to peanuts, milk, or soy",{"count":266,"type":22},100,[61],"Small Quantity Lipid-based Nutrient Supplements (SQ-LNS), are fortified, lipid-based nutritional supplements that were specifically designed for children 6-24 months to prevent malnutrition. Recent research has shown reductions in mortality, severe wasting, severe stunting, iron deficiency anemia, and developmental delays.\n\nSQ-LNS is currently available in individual daily dose packets of 20g. Healthy children age 6-24 months receive 1 packet per day (1dp), and are typically given a 1- or 2- month supply at a time (30-60 packets).\n\nRecently, Nutriset Développement has developed a new packaging design for SQ-LNS that reduces the cost by over 15% overall, through production efficiency with 40% less packaging, and improved transportation efficiency by 20%. This new packaging is a 140g packet that will allow 20g to be dispensed daily for 7 days (7dp). The packaging has a chamber that will allow for accurate 10g dosing (either twice daily, or twice at once). Users of the packaging will also be able to close the spout to minimize risk of microbiological contamination.\n\nEdesia Nutrition is working with Nutriset to conduct field testing of this new packaging for SQ-LNS, and this mixed-methods study in North Shoa Zone, Amhara Region, Ethiopia, will help inform recommendations for the future use of the package. The study seeks to determine (1) the acceptability of integrating SQ-LNS distribution into the malnutrition program; (2) whether adherence to the 2 different package types differs, and if there are differences in usage; (3) and how the packages perform over time, their perceived safety and functionality, and how they are stored.\n\nEducational and communication tools will be developed and pre-tested as part of this study, and will become part of the final deliverable package to Edesia Nutrition, in addition to final recommendations on the product packaging, findings about how the packages are used, and behavior change and nutrition education strategies.\n\nThe primary outcome of the quantitative evaluation will be adherence, calculated as the number of delivered doses of SQ-LNS divided by the number of expected doses per week (7).\n\nAdherence will be measured via weekly self-report via caregiver interview and counts of return of used and unused packages during weekly home visits. The percentage of children who receive a dose during structured observation periods will be calculated. Each adherence outcome will be analyzed separately.",[270,271,272],"Prevention","Malnutrition, Child","Nutrition",[274,275,276],"Small Quantity Lipid-based Nutrient Supplement","Child nutrition","Malnutrition prevention",{"date":278,"type":39},"2026-05-14",{"date":280,"type":22},"2026-05",{"date":282,"type":22},"2026-12",{"name":284,"class":46},"University of California, San Francisco",{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":228,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":59,"phases":294,"briefSummary":295,"conditions":296,"keywords":298,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":78},"100628493","system-integrated-point-of-care-ultrasound-in-breast-cancer-screening-100628493","NCT07462351","System-integrated Point-of-Care Ultrasound in Breast Cancer Screening","SPRING","Inclusion Criteria:\n\n* Asymptomatic women from the age of 30 with no upper age limit\n* Symptomatic women 18 years or older.\n\nExclusion Criteria:\n\n* Individuals unable to comprehend the study information due to language barriers or cognitive impairments.",{"count":293,"type":22},4800,[61],"To assess the feasibility, safety, and clinical performance of community-based breast cancer screening incorporating clinical breast exam and short-termed trained examiners performing AI-supported breast POCUS for triage in limited-resource settings.",[297],"Breast Cancer",[299,300,301,302,303,304,305],"Screening","Low- and middle-income countries","Global health","Artificial intelligence","Ultrasound","Point-of-care ultrasound","clinical breast exam","2026-04-07",{"date":308,"type":39},"2026-04-13",{"date":310,"type":39},"2026-03-11",{"date":312,"type":22},"2026-12-31",{"name":314,"class":46},"Region Skane",{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":228,"sex":55,"minAge":323,"maxAge":324,"enrollmentInfo":325,"targetDuration":4,"studyType":59,"phases":327,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":78},"100633081","social-networks-for-improving-maternal--child-health-100633081","NCT07522047","Social Networks for Improving Maternal & Child Health","Improving the Health and Nutritional Status of Mothers and Children Using Indigenous Community Structure in Northwest Ethiopia","SoNIMCH","Inclusion Criteria:\n\nPregnant women residing in the selected study clusters (kebeles)\n\nPregnant women who are in their first trimester (gestational age less than 16 weeks) at the time of recruitment.\n\nPregnant women who intend to reside in the study area for the duration of the pregnancy and at least six months postpartum.\n\nExclusion Criteria:\n\nPregnant women with known pre-existing chronic medical conditions (e.g., chronic hypertension, diabetes mellitus, or cardiac disease) that require specialized medical management.\n\nPregnant women who are unable to communicate or undergo the interview process due to severe illness or cognitive impairment.\n\nPregnant women who are already participating in another clinical trial or health intervention study.","15 Years","49 Years",{"count":326,"type":22},700,[61],"Brief Summary: Improving Maternal and Child Health via Indigenous Structures\n\nThe goal of this cluster randomized controlled community trial is to assess the effect of community-based interventions using indigenous community structures on the improvement of health and nutritional status in pregnant women (recruited before 16 weeks of gestation) and their children in Northwest Ethiopia. The main questions it aims to answer are:\n\n* Does a community-based intervention using indigenous structures significantly improve the uptake of maternal health services (ANC, delivery, and PNC)?\n* Does the intervention effectively reduce the prevalence of maternal depression during the pregnancy and postpartum periods?\n* To what extent does the intervention improve the nutritional status (reducing thinness and stunting) of mothers and their children? Researchers will compare a group of women receiving counseling from trained indigenous social support groups to a control group receiving only the routine health and nutrition education provided by the standard healthcare system to see if the indigenous approach leads to better health and nutritional outcomes.\n\nParticipants will:\n\n* Receive four counseling sessions during pregnancy (starting before 16 weeks of gestation) and four additional sessions during the lactation period, conducted in their homes by trained social support groups.\n* Receive educational leaflets containing core health and nutrition messages and appropriate pictures.\n* Participate in two rounds of surveys (baseline, and endline) involving interviewer-administered questionnaires.\n* Undergo physical measurements, specifically mid-upper arm circumference (MUAC), to assess nutritional status.",[330,331],"Maternal and Child Health","Maternal Nutrition","2026-04-03",{"date":308,"type":39},{"date":335,"type":22},"2026-04-01",{"date":337,"type":22},"2028-06-30",{"name":339,"class":46},"Bahir Dar University",{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":228,"sex":18,"minAge":347,"maxAge":348,"enrollmentInfo":349,"targetDuration":4,"studyType":59,"phases":351,"briefSummary":352,"conditions":353,"keywords":357,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":364,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":78},"100631906","quality-of-home-packed-school-lunch-among-children-attending-kindergarten-school-in-jimma-zone-south-west-ethiopia-2026-100631906","NCT07506772","Quality of Home Packed School Lunch Among Children Attending Kindergarten School in Jimma Zone, South West Ethiopia, 2026","Effect of Nutrition Education on the Diet Quality of Home Packed School Lunch Among Preschool Children Attending Kindergarten School in Jimma Zone, South West Ethiopia, 2026","Inclusion criteria\n\n* Children aged 4-7 years attending kindergarten schools in the selected clusters.\n* Parents or caregivers willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Students who will not finish the school year\u002Fintervention semister in the selected cluster\u002Fschool.\n* Mothers\u002Fcaregivers who will not give consent for the participation in the study will be excluded.","4 Years","7 Years",{"count":350,"type":22},451,[61],"A balanced diet is critical for preschool aged children; meals must be sufficiently diverse to provide the essential nutrients required for rapid physical and cognitive development. Because dietary habits established in early childhood often persist into adulthood, prioritizing this age group is a cost-effective investment in long-term national health and productivity. However, the National Food Consumption Survey in Ethiopia indicates a significant gap in dietary quality, with only 20% of households across all age groups consuming five or more food groups. Implementing multi-component nutrition interventions is essential, as these strategies significantly influence both the eating habits and dietary preferences of preschool children.",[354,355,356],"Healthy Eating","Food Preference","Nutritional Status",[358,359,360,361,362,363,94],"Preschool children","Kindergarten","Cluster Randomised control trial","Nutrition education","Diet Quality","Cluster Randomized Controlled Trial",{"date":306,"type":39},{"date":366,"type":39},"2026-01-01",{"date":368,"type":22},"2026-06-30",{"name":370,"class":46},"Jimma University",{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":18,"minAge":379,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":59,"phases":382,"briefSummary":383,"conditions":384,"keywords":397,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":416,"leadSponsor":418,"locationsCount":420},"100631921","early-detection-and-ai-based-management-of-skin-related-neglected-tropical-diseases-in-sub-saharan-africa-by-frontline-health-workers-100631921","NCT07506967","Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers","Early Detection and Management of SKIN-related negleCted Tropical Diseases Using Artificial Intelligence in Sub-saharan afRica (SkincAIr)","SkincAIr","1. Frontline Health Workers (FHWs) Age Group\n\n   * Age Range: 18 years and above o Justification: FHWs must be adults, legally eligible to provide healthcare services and consent to participate in the study Sex Distribution\n   * Male and Female FHWs o Justification: Both male and female FHWs will be included to reflect the actual workforce distribution and to ensure generalizability of the results across genders.\n\n   Inclusion criteria for FHWs:\n   1. Professional Role:\n\n      o Must be working as a FHW at one of the selected health centers at the time of the validation study.\n\n      ▪ Justification: The study aims to assess the diagnostic performance of those directly involved in primary patient care in the targeted settings.\n   2. Willingness to Participate:\n\n      o Willing to provide written informed consent to participate in the study.\n\n      ▪ Justification: Ethical standards require voluntary participation with informed consent.\n   3. Smartphone Usage:\n\n      o Willing and able to use a smartphone during the study.\n\n      ▪ Justification: The SkincAIr app is smartphone-based; therefore, FHWs must be willing to use and have access to such devices.\n   4. No Specialized Dermatology Training:\n\n      * FHWs without specialised training in dermatology or extensive experience in skin disease diagnosis.\n\n        * Justification: The study aims to evaluate the app's effectiveness among generalist healthcare workers who would benefit most from diagnostic support tools.\n\n   Exclusion criteria for FHWs:\n\n   1\\. Prior Specialised Training in dermatology:\n\n   o FHWs with formal education or extensive experience in dermatology.\n   * Justification: Including specialists could skew results, as their baseline diagnostic accuracy may already be high, reducing the observable impact of the app.\n\n     2\\. Refusal or Inability to Consent:\n     * FHWs unwilling or unable to provide written informed consent.\n   * Justification: Ethical compliance requires informed consent for participation. 3. Inability to Use the App: o FHWs unable to use a smartphone due to technical limitations, physical impairments, or lack of familiarity with the technology.\n   * Justification: Effective use of the app is essential for the intervention; inability to use it would prevent meaningful participation.\n2. Patients with Skin complaints Size\n\n   ● Total Patients: \\~750 patients Age Group\n\n   ● All Age Groups:\n\n   o Justification: Skin-NTDs affect individuals of all ages; including all age groups enhances the generalizability of the findings and assesses the app's effectiveness across the lifespan.\n\n   Sex Distribution\n   * Male and Female Patients\n   * Justification: Both sexes are included to capture the full spectrum of the disease burden and ensure the app's diagnostic accuracy is effective regardless of sex.\n\n   Inclusion Criteria for Patients with Skin complaints:\n\n   1\\. Presenting with Skin Complaints:\n\n   o Patients presenting to participating health centres with symptoms suggestive of skin-NTDs (e.g., visible skin lesions, nodules, ulcers) but have not been diagnosed by a specialist for that specific skin condition.\n   * Justification: The study aims to evaluate the app's effectiveness in real-world conditions, including all patients with potential skin-NTDs 2. Willingness to Participate: o Patients (or guardians, in the case of minors) willing to provide written informed consent for participation.\n   * Justification: Ethical standards require informed consent from patients or their legal guardians.\n\n     3\\. Ability to Comply with Study Procedures:\n\n     o Patients are able to follow study instructions and attend necessary follow-up appointments.\n   * Justification: Ensures complete data collection and accurate assessment of outcomes.\n\n     4\\. Patients with Co-morbid conditions:\n   * Justification: Immunosuppression that occurs in some comorbid conditions e.g. HIV\u002FAIDS or severe malnutrition can reveal the Skin disease and can affect both the clinical progression and even severity of the Skin NTD. This also includes patients with multiple skin-NTDs.\n\n   Exclusion Criteria for Patients with Skin complaints:\n   1. Refusal or Inability to Consent:\n\n      o Patients (or guardians) unwilling or unable to provide written informed consent.\n\n      ▪ Justification: Ethical compliance requires informed consent for participation.\n   2. Non-Skin-Related Complaints:\n\n      o Patients presenting with complaints unrelated to skin conditions.\n\n      ▪ Justification: The study focuses on skin-NTDs; including unrelated cases would not contribute to the study objectives.\n   3. Previous Participation in the Study:\n\n      o Patients who have already participated in the study.\n\n      ▪ Justification: To avoid duplicate data and potential bias in outcomes.\n\n      Additional Considerations:\n\n      Diversity and Representation ● Geographical Diversity:\n\n      o Including health centres from different regions within each country ensures that the findings are representative of various settings (urban, peri-urban, rural).\n\n      ● Cultural and Socioeconomic Factors:\n\n      o The study acknowledges that cultural beliefs and socioeconomic status may influence healthcare-seeking behaviour and disease presentation. By including a diverse patient population, the study aims to capture these variations.\n\n      Ethical Justification ● Inclusivity:\n      * Including all age groups and both sexes aligns with ethical principles of justice and fairness, ensuring that the benefits of the research are accessible to all segments of the population.\n\n        * Vulnerable Populations:\n      * While including minors and potentially vulnerable adults, the study will implement additional safeguards to protect their rights and well-being, following ethical guidelines and obtaining consent from guardians when necessary.","0 Years",{"count":381,"type":22},2420,[61],"Skin-related Neglected Tropical Diseases (Skin NTDs) affect about 1.8 billion people worldwide, particularly in poor and rural communities where healthcare access is limited. Many people rely on frontline health workers (FHWs) for treatment, but these workers often lack specialized training in skin diseases, making diagnosis difficult. To address this challenge, the SkincAIr project is testing whether a mobile app powered by artificial intelligence (AI) can help FHWs improve their ability to detect Skin NTDs. The study will be conducted in two arms. In the first clinical image data collection arm (36 months), dermatologists in 5 countries (Kenya, Ethiopia, Senegal, Democratic Republic of Congo and Nigeria) will collect images of skin NTD and other skin conditions that will be used for development and training of the AI model within the SkincAIr app before it is tested among FHWs. The second validation study arm will take place in 3 countries (Kenya, Ethiopia and Senegal), and will involve 50 FHWs and around 750 patients in each country over 24 months. During the first 12 months (Phase A), FHWs will diagnose patients using standard methods without the app, establishing baseline performance on key indicators including diagnostic accuracy, time to diagnosis, referral patterns, and cost implications of improved primary-level diagnosis. For the following 6 months (Phase B), FHWs will use the SkincAIr app with AI functionality activated to support diagnosis and enable real-time geolocated disease mapping and hotspot identification. In the final 6 months (Phase C), the app is withdrawn to assess whether FHWs retain their improved diagnostic skills. We will summarize the results using simple numbers and charts to show how often things happen and what the average results look like. Researchers will evaluate how well the app improves diagnosis by FHWs and whether FHWs retain their improved skills even after AI support is removed, by comparing their results with those of a skin specialist (dermatologist). Interviews and group discussions will be recorded, written down, organized into key ideas, and carefully reviewed using a computer program to understand the main themes. Study findings will be shared with National Ministries of Health, presented at local and international conferences, and reported to relevant institutional and regulatory authorities. If successful, this AI tool could boost early detection of skin diseases, enhance disease tracking, and improve healthcare in underserved areas.",[385,386,387,388,180,389,390,391,392,393,394,395,396],"Skin and Connective Tissue Diseases","Neglected Tropical Diseases","Leprosy","Buruli Ulcer","Scabies","Mycetoma","Lymphatic Filariasis","Onchocerciasis","Tungiasis","Post Kala-Azar Dermal Leishmaniasis","Yaws","Podoconiosis",[398,399,400,401,402,403,404,405,240,406,407,408,94,409,410,411],"Skin-related neglected tropical diseases","Artificial Intelligence","Mobile Health","mHealth","Frontline Health Workers","Diagnostic Accuracy","Sub-Saharan Africa","Skin NTDs","AI Diagnostic Tool","Capacity Building","Kenya","Senegal","Nigeria","Democratic Republic of the Congo","2026-03-27",{"date":414,"type":39},"2026-04-02",{"date":73,"type":22},{"date":417,"type":22},"2030-05-31",{"name":419,"class":46},"Kenya Medical Research Institute",5,{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":228,"sex":18,"minAge":19,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":59,"phases":432,"briefSummary":433,"conditions":434,"keywords":437,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":78},"100545330","increasing-the-coverage-of-severe-acute-malnutrition-sam-treatment-in-ethiopia-100545330","NCT06380504","Increasing the Coverage of Severe Acute Malnutrition (SAM) Treatment in Ethiopia","Effect of Leveraging Community-level Structures to Strengthen Prevention, Screening and Treatment of Severe Acute Malnutrition in Ethiopia","R-SWITCH","Inclusion Criteria:\n\n* Child 6-59 months of age\n* Suffering from SAM (defined as MUAC \\\u003C 115mm or presence of bilateral pitting edema or Weight-for-Length Z-score \\\u003C-3) OR currently enrolled in SAM OTP\n\nExclusion Criteria:\n\n\\- Anthropometric malformation or being handicapped which hampers anthropometric measurements.","5 Years",{"count":431,"type":22},1080,[61],"The R-SWITCH intervention aims to address the low coverage of treatment for severe wasting (SAM) by leveraging existing community groups to deliver an integrated package focused on prevention, screening, referral, and treatment of SAM. It includes behavior change communication on child nutrition and health, active screening, improved passive screening at health posts, and follow-up of referred cases and those enrolled in outpatient treatment programs (OTP). The primary objectives of the R-SWITCH studies are to assess the intervention's impact on OTP coverage, identify implementation barriers and facilitators, and evaluate its cost-efficiency and cost-effectiveness.",[435,271,436],"Acute Malnutrition, Severe","Wasting",[438,439,299,436,440],"Outpatient Therapeutic Feeding Program","Treatment","Severe acute malnutrition","2026-03-25",{"date":412,"type":39},{"date":444,"type":39},"2024-05-02",{"date":446,"type":22},"2027-06-30",{"name":448,"class":46},"International Food Policy Research Institute",{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":18,"minAge":457,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":59,"phases":460,"briefSummary":462,"conditions":463,"keywords":468,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":485},"100587069","phase-3-serological-testing-and-treatment-for-plasmodium-vivax-malaria-a-trial-in-ethiopia-and-madagascar-100587069","NCT06923592","Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar","Serological Testing and Treatment for Plasmodium Vivax Malaria: a Cluster-Randomised Trial in Ethiopia and Madagascar","PvSTATEM","Inclusion Criteria:\n\n* Participant will remain in the study area for at least the next month.\n* Participant is older than 12 months\n\nExclusion Criteria:\n\n• Participant is unwilling to participate.","12 Months",{"count":459,"type":22},19200,[461],"PHASE3","The resilience of P. vivax to malaria elimination efforts is due to its ability to form dormant liver stages (hypnozoites) that reactivate weeks to months after the initial infection causing recurrent episodes of malaria (relapses) and ongoing parasite transmission. Relapses account for a majority of recurrent infections and clinical cases of P. vivax malaria, and therefore have a significant effect on morbidity at the individual level.\n\nWith current technology, it is not possible to directly measure hypnozoite biomarkers. Rather than directly detecting hypnozoites, our team developed an indirect approach by measuring antibodies induced by the primary blood-stage infection. Antibodies to different blood-stage antigens decay at different rates. Measuring antibodies to a carefully selected panel of P. vivax antigens can aid to identify individuals who have been infected within the previous 9 months (approximately the lifespan of hypnozoites).\n\nA serological test based on selected P. vivax antigens can detect recent exposure and predict future relapses. Coupling this test with a safe and efficacious primaquine treatment regimen, results in a population-based intervention to target the hypnozoite reservoir. This intervention is referred to as Plasmodium vivax Serological Testing and Treatment (PvSeroTAT).\n\nPvSTATEM is a cluster randomised trial in Madagascar and Ethiopia. This study will provide insights into the feasibility, acceptability, and efficacy of the PvSeroTAT approach. In this study, individuals, randomised by clusters, will be tested for the presence of serological markers of a recent P. vivax infection, followed by a targeted drug treatment intervention aimed at killing P. vivax hypnozoites.",[464,465,466,467],"Malaria Vivax","Malaria Falciparum","Plasmodium Vivax","Plasmodium Falciparum",[469,470,471,455,472,473,474,475],"Plasmodium vivax","Vivax","PvSeroTAT","Primaquine","serology","Cluster randomised trial","G6PD","2026-03-19",{"date":478,"type":39},"2026-03-24",{"date":480,"type":39},"2025-05-12",{"date":482,"type":22},"2027-04-28",{"name":484,"class":46},"London School of Hygiene and Tropical Medicine",2,{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":492,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":496,"conditions":497,"keywords":500,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":78},"100630413","recurrent-visceral-leishmaniasis-in-hiv-co-infection-100630413","NCT07487350","Recurrent Visceral Leishmaniasis in HIV Co-Infection","New And Recurrent Visceral Leishmaniasis in HIV Co-Infected Ethiopian Patients: a Cohort Study","ALIVE","Inclusion Criteria:\n\n1. VL-HIV infection 1.1. VL: microscopically confirmed parasite presence in spleen or bone marrow tissue at first episode or relapse; for known active chronic cases: decision to treat VL 1.2. HIV: confirmed viral infection (new or past)\n2. ≥18 years\n\nExclusion Criteria:\n\n1. Not willing to provide written informed consent\n2. Not willing to adhere to the follow-up visits\n3. Mentally or physically incapable to participate in the study (to the discretion of the treating physician)",{"count":495,"type":22},20,"The aim is (1) to better understand the underlying causes and predispositions for relapse and parasite persistence in visceral leishmaniasis (VL) patients living with HIV and (2) to improve treatment monitoring of this target group in Ethiopia",[498,499],"Hiv","Visceral Leishmaniasis",[501,502,503,504],"HIV","VL","VL Relapse","Immune exhaustion","2026-03-17",{"date":507,"type":39},"2026-03-23",{"date":509,"type":39},"2025-10-21",{"date":511,"type":22},"2027-12",{"name":513,"class":46},"Institute of Tropical Medicine, Belgium",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":521,"enrollmentInfo":522,"targetDuration":4,"studyType":59,"phases":524,"briefSummary":525,"conditions":526,"keywords":528,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":78},"100629773","a-home-based-approach-to-tuberculosis-preventive-treatment-management-100629773","NCT07479030","A Home-Based Approach to Tuberculosis Preventive Treatment Management","Evaluating the Effectiveness of a Home-Based Approach to Tuberculosis Preventive Treatment Management Among Child Household Contacts in Gedeo Zone, Southern Ethiopia: A Cluster-Randomized Trial","Inclusion Criteria:\n\n* Index patients will be eligible if they are at least eighteen years old, live within the facility's catchment area, have been diagnosed with pulmonary tuberculosis within the last month (either bacteriologically confirmed or clinically diagnosed), report at least one child contact below 15 years of age, and are willing to participate in a home visit and give written informed consent and\u002For assent.\n\nExclusion Criteria:\n\n* Children will be excluded if there is evidence of drug-resistant tuberculosis based on Xpert MTB\u002FRIF® results. Additionally, children will be excluded if a pediatrician's clinical assessment identifies a contraindication to TPT, where the anticipated risk is deemed to outweigh the potential benefit of initiating therapy. Furthermore, child contacts currently receiving TPT or treatment for active TB will be excluded.","14 Years",{"count":523,"type":22},1300,[61],"Background: Tuberculosis (TB), though preventable and curable, remains a major public health concern worldwide. While elimination of tuberculosis infection (TBI) is critical to TB elimination, TBI continues to represent a substantial public health burden, particularly among household contacts.\n\nIn recent years, tuberculosis preventive treatment (TPT) has been recognized as essential to eliminating TB worldwide and is particularly critical for children with TBI or close contacts of individuals with infectious TB. The scale-up of TPT among household contacts has been markedly slow, with only 55% of the coverage target achieved for children under 5 years and only 10% for those over 5 years by 2022, highlighting substantial gaps in preventive intervention implementation.\n\nCommunity- and home-based approaches are proposed solutions to reduce the gaps in early detection and provision of preventive treatment for household contacts in high-TB-burden settings many of whom remain underserved with the usual standard facility care. A home-based approach has not been well evaluated for its effectiveness in real-world settings to inform policy decisions. Given the limited evidence, this study aims to evaluate the effectiveness of a home-based TB contact investigation and preventive treatment management among child household contacts in southern Ethiopia.\n\nObjective: This study aims to evaluate the effectiveness of a home-based TB contact investigation and preventive treatment management among child household contacts in Gedeo, South Ethiopia.\n\nMethods: A pragmatic, two-arm, parallel, cluster-randomized trial will be conducted in Gedeo, South Ethiopia. The procedures in this trial will be based on eight clinical standards for the diagnosis, treatment, and prevention of TBI, which were defined through a Delphi process by a panel of global experts in tuberculosis care. This trial consists of two study groups: a home-based intervention group and a standard facility-based (usual care) comparison group.\n\nWithin the intervention group, health extension workers based at health posts in the catchment areas of the selected clusters will receive training focused on the study procedures-the implementation of standardized TB symptom screening protocols, TPT management and adherence support, and safety assessment and reporting. A routine TB care procedure will be implemented in the facilities randomized to the comparison group in accordance with national guidelines. Index patients will be asked to enumerate and bring all children below 15 years of age for TB screening and initiation of preventive treatment or anti-TB treatment accordingly.",[527],"Tuberculosis",[529,530,531,532,533,534,535,94],"Effectiveness","Household contacts","Home-based approach","Tuberculosis preventive treatment","Contact investigation","Children","Health Extension Workers","2026-03-13",{"date":538,"type":39},"2026-03-18",{"date":540,"type":22},"2026-04-15",{"date":542,"type":22},"2027-10-14",{"name":544,"class":46},"Dilla University",{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":549,"acronym":4,"eligibilityCriteria":550,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":551,"targetDuration":4,"studyType":59,"phases":552,"briefSummary":554,"conditions":555,"keywords":558,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":258},"100628966","phase-4-primaquine-for-vivax-malaria-in-g6pd-intermediate-and-deficient-cases-100628966","NCT07468513","Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.","Inclusion Criteria:\n\n* • P. vivax peripheral parasitaemia (mono-infection)\n\n  * G6PD intermediate or deficient status (G6PD activity 30-\\\u003C70% or ≤30% of the adjusted male median as determined by the Standard G6PD (SDBioline, ROK))\n  * Fever (temperature ≥37.5⁰C) or history of fever in the preceding 48 hours\n  * Age ≥18 years\n  * Haemoglobin at presentation ≥8g\u002Fdl\n  * Written informed consent\n  * Living in the study area and willing to be followed for six months.\n\nExclusion Criteria:\n\n* • Danger signs or symptoms of severe malaria\n\n  * Pregnant or lactating females\n  * Regular use of drugs with haemolytic potential\n  * Known hypersensitivity to any of the study drugs.",{"count":266,"type":22},[553],"PHASE4","A non randomized observation study that is aiming to assess the safety and efficacy of high dose primaquine (1mg\u002Fkg per day over 7 days) among patients with intermediate (30-70%) G6PD activity and the safety and efficacy of weekly primaquine among patients who are g6Pd deficient (\\\u003C30% activity)",[556,557],"Vivax Malaria","G6PD Deficiency",[559,560],"Primaquine in G6PD deficiency","Vivax malaria in G6PD deficient patients","2026-03-09",{"date":563,"type":39},"2026-03-12",{"date":565,"type":39},"2024-05-17",{"date":567,"type":22},"2028-12-31",{"name":569,"class":46},"Menzies School of Health Research",{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":576,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":18,"minAge":429,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":59,"phases":580,"briefSummary":581,"conditions":582,"keywords":584,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":586,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":420},"100628967","phase-3-an-ultra-short-course-of-primaquine-for-the-radical-cure-of-vivax-malaria-100628967","NCT07468526","An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria","An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria (PRIMUS)","PRIMUS","Inclusion Criteria:\n\n* P. vivax peripheral parasitaemia as determined by microscopy\n* G6PD normal status (G6PD activity ≥70% of the site specific adjusted male median as determined by the Standard G6PD (SD Bioline, ROK))\n* Fever (temperature ≥37.5°C) or history of fever in the preceding 48 hours,\n* Age ≥5 years\n* Bodyweight ≥14kg\n* Living in the study area and willing to be followed-up for six months\n\nExclusion Criteria:\n\n* Signs or symptoms of severe malaria,\n* Anaemia (defined as Hb \\\u003C8g\u002Fdl) and measured by the Standard G6PD\n* Pregnant or lactating\n* Blood transfusion within the preceding four months\n* Regular or recent use (last month) of tafenoquine, primaquine or dapsone\n* Known hypersensitivity to any of the study drugs",{"count":579,"type":22},1019,[461],"Current treatment regimens to prevent relapsing malaria are too long. A shorter higher dose treatment could improve treatment outcomes, but this needs to be balanced against increased risk of side effects. Recent data from a trial in children in Papua New Guinea (PNG) suggests a shortened treatment of 3 days is safe and effective. Our multicentre trial will assess the safety and efficacy of an ultra-short primaquine course. This trial is expected to directly influence global treatment policies.",[583],"Malaria",[585,576],"An ultra-short course of primaquine for the radical cure of vivax malaria",{"date":563,"type":39},{"date":588,"type":22},"2026-06-01",{"date":590,"type":22},"2028-04-01",{"name":569,"class":46},{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":18,"minAge":347,"maxAge":117,"enrollmentInfo":599,"targetDuration":4,"studyType":59,"phases":601,"briefSummary":602,"conditions":603,"keywords":605,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":47},"100628546","phase-3-study-comparing-several-drugs-to-understand-which-work-against-cutaneous-leishmaniasis-cl-100628546","NCT07463040","Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)","A Multi-Arm, Multi-Stage Randomized Controlled Clinical Trial Evaluating Systemic Therapeutic Regimens for the Treatment of Cutaneous Leishmaniasis in Ethiopia","Inclusion Criteria:\n\n* Parasitological (microscopy, culture or PCR) confirmation of leishmaniasis\n* Age ≥4 and ≤65 years old\n* Need systemic treatment based on meeting at least one of the following criteria: \\>4 lesions\u002F At least one with lesion size \\>4cm\u002F Mucosal involvement, or at risk for mucosal involvement (\\\u003C1 cm from the nose, eyes or vermillion border of the lips)\u002F Previous failure of lesion-directed treatment \u002FLesions on areas not suitable for lesion-directed therapy (e.g. joints, eyelids, fingers)\u002F Deep or extensive lesion(s) with risk of functional impairment\n* Informed consent provided, as follows: For patients ≥18 years of age: Patient is willing and able to provide informed consent. \u002F For patients aged 8 to 17 years (inclusive): Parent or caregiver is willing and able to provide informed consent, and patient is willing and able to provide assent \u002F For patients aged 4 to 7 years (inclusive): Parent or caregiver is willing and able to provide informed consent.\n* Willing and able to be hospitalized for the duration of treatment\n* Willing and able to attend all follow-up visits\n* If female and of child-bearing age: willing to take contraceptives during treatment and for 5 months after EoT (parenteral, intrauterine device (IUD) or implant). Note that actually taking the contraceptives is only required when randomized in an investigational arm containing miltefosine.\n\nExclusion Criteria:\n\n* Pregnant (positive pregnancy test at screening) or breastfeeding\n* Any known severe medical comorbidities, or signs and symptoms of severe disease, that in the opinion of the investigator disqualifies the patient of being enrolled in the trial or precludes evaluation of the patient's response to the study medication. Examples are: Severe known active infections such as tuberculosis, schistosomiasis, malaria, hepatitis B virus, active hepatitis C virus\u002F Serious underlying disease (e.g. cardiac, renal, hepatic (including diabetes mellitus) or chronic disease\u002F Immunocompromising conditions: transplant patients, or patients receiving immunosuppressant medication\u002F Pre-existing ocular conditions evaluated at baseline: e.g. keratitis, uveitis, scleritis\u002F Pre-existing sensorineural hearing loss evaluated at baseline, or previously diagnosed with ototoxicity\n* HIV Infection\n* Severe malnutrition: ≤5 years old: Mean upper arm circumference (MUAC) \\\u003C115mm\u002F 6-10 years old: MUAC \\\u003C135mm\u002F 11-17 years old: MUAC \\\u003C160mm\u002F ≥ 18 years old: Body mass index (BMI) \\\u003C16kg\u002Fm²\n* (History of) ECG abnormalities: Clinically significant cardiac arrythmias: e.g. 2nd degree or 3rd degree AV block without pacemaker, sustained ventricular tachycardia\u002F Prolonged QTc interval \\>450ms\n* Lab abnormalities: Haemoglobin \\\u003C5.0g\u002FdL\u002F Platelets \\\u003C50 x 10\\^9\u002FL\u002F White blood count \\\u003C1 x 10\\^9\u002FL \u002F Alanine aminotransferase (AST) \u002F aspartate aminotransferase (ALT) \\>3x upper limit of normal (ULN)\u002F Serum creatinine \\>1.5 x ULN\u002F Bilirubin \\>1.5 x ULN\u002F Fasting blood glucose (preferred) \\>7mmol\u002FL (126mg\u002Fdl) or blood glucose \\>11.1 mmol\u002FL (200mg\u002Fdl) at any time\u002F Potassium \\\u003C3.5mmol\u002FL\n* Having received any allopathic treatment for CL lesion(s) in the past 6 months: cryotherapy, thermotherapy, SSG, meglumine antimoniate, paromomycin, pentamidine, liposomal amphotericin B, non-liposomal amphotericin B, miltefosine\n* Diffuse cutaneous leishmaniasis (DCL)\n* Patients on treatment with any of the prohibited medications, which are any treatments with the potential to influence lesion healing, skin condition, or participant safety. This includes any form of chemotherapy, antituberculosis medication, systemic antibiotics or antifungals, antivirals, corticosteroids and immunosuppressants. Topical antibiotics or antifungals are allowed as long as they are not applied on any of the CL lesions.\n* Onset of lesions \\>24 months ago\n* Known allergies or serious adverse reactions to one of the study components\u002Fmedications\n* Any other condition for which participation in the trial, as judged by the investigator, could compromise the well-being of the patient or prevent, limit or confound protocol-specified assessments",{"count":600,"type":22},900,[461],"MAMS4CL comprises a clinical trial with three embedded sub-studies designed to comprehensively evaluate the administered treatments and assess the impact of CL treatment on patients and the healthcare system.\n\nThe multi-centre multi-arm multi-stage phase 3 clinical trial is designed to rigorously evaluate a total of 4 alternative treatment options for systemic CL against Sodium Stibugluconate (SSG) as the standard of care. The trial comprises two seamlessly linked stages. In stage 1, all four investigational arms will be evaluated against the control arm for efficacy to inform the selection of the arms, based on a pre-defined efficacy threshold that will advance to stage 2, in addition to the control arm. After stage 2, the experimental interventions will be compared with SSG similar to a standard superiority trial for efficacy. The general study design in stage 1 and stage 2 will be identical; only the number of investigational arms may differ.\n\nPatients will be randomized into the respective treatment arms at the recruitment sites of Arba Minch hospital, Boru Meda hospital and ALERT hospital in Ethiopia. Individuals will be hospitalized during the entire course of their treatment. As different arms have different treatment duration, patient hospitalization period and visit schedules will differ between arms. In total, the study will last 180 days for each participant.",[604],"Cutaneous Leihmaniasis",[606,607,608,609,610,611,612,94,613],"Multi-Arm Multi-Stage","Standard of care","Sodium stibogluconate","Miltefosine","Paromomycin","Liposomal amphotericin B","Pentamidine","cutaneous Leishmaniasis","2026-03-06",{"date":616,"type":39},"2026-03-10",{"date":618,"type":22},"2027-01-01",{"date":620,"type":22},"2029-08-31",{"name":513,"class":46},{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":627,"acronym":4,"eligibilityCriteria":628,"healthyVolunteers":12,"sex":18,"minAge":521,"maxAge":629,"enrollmentInfo":630,"targetDuration":4,"studyType":59,"phases":632,"briefSummary":633,"conditions":634,"keywords":638,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":649,"locationsCount":420},"100625691","digital-peer-support-based-anti-hiv-stigma-intervention-among-adolescents-living-with-hiv-in-ethiopia-100625691","NCT07425925","Digital Peer-support-based Anti-HIV Stigma Intervention Among Adolescents Living With HIV in Ethiopia","Feasibility and Effectiveness of Digital Peer-support-based Anti-HIV Stigma Intervention in Improving Clinical Outcomes Among Adolescents Living With HIV in Ethiopia","Inclusion Criteria:\n\n* Adolescents who have been disclosed of their HIV status\n* adolescents and young people between the age of 15 and 22 years old\n* receiving antiretroviral medications; and\n* completed at least first cycle primary school education (i.e. grade 4).\n\nExclusion Criteria:\n\n* Participants with known diagnosed mental health condition\n* Participants with hearing loss or loss of vision","22 Years",{"count":631,"type":22},282,[61],"Advances in HIV care and treatment turned a once deadly disease into a chronic condition where people living with HIV, including perinatally HIV acquired children, can now lead a healthy life and live longer with their highly effective antiretroviral therapy. Despite the advancements and successes in HIV care and treatment, HIV-related stigma remained a challenge to people living with HIV and for the provision of the available successful treatment and support. Stigma and discrimination related to HIV infection inhibit health-seeking behaviour, clinical outcomes, physical and psychosocial wellbeing and is a major obstacle for timely diagnosis.\n\nPeer support programs to people living with HIV appeared to have improved self-confidence of members and consequently reduced self-stigma and improved their coping ability against external stigma. However, these services are limited in terms of geography owing to lack of adequate financing to cover operational costs for adolescents coming from rural areas and space and facility limitation to accommodate large groups.\n\nThe eHealth services have potential to provide some of the services offered in the in-person sessions of the peer support group. Despite this important potential of eHealth services, they are underutilized and are not often used to target HIV-related stigma in adolescents living with HIV. The present study will investigate whether the digital peer-support anti-HIV stigma reduces internalized and anticipated stigma among adolescents living with HIV (ALHIV) in South Ethiopia. Further, we will explore the health-related outcomes including adolescent's psychological wellbeing, retention in care and sustained viral load suppression.",[635,636,637],"HIV-related Stigma","Psychological Wellbeing","Retention in Care",[639,640,641,642],"digital peer-support","HIV-related stigma","adolescents living with HIV","south Ethiopia","2026-02-19",{"date":645,"type":39},"2026-02-23",{"date":647,"type":39},"2025-11-13",{"date":73,"type":22},{"name":650,"class":46},"Lund University",{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":656,"acronym":4,"eligibilityCriteria":657,"healthyVolunteers":12,"sex":18,"minAge":658,"maxAge":659,"enrollmentInfo":660,"targetDuration":4,"studyType":59,"phases":662,"briefSummary":663,"conditions":664,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":668,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":485},"100548834","l-citrulline-to-improve-adverse-outcomes-in-admitted-children-echilibrist-clinical-trial-2-inpatients-100548834","NCT06426147","L-citrulline to Improve Adverse Outcomes in Admitted Children (EChiLiBRiST, Clinical Trial 2, Inpatients)","A Randomised, Double-blind, Placebo-controlled Trial of L-Citrulline Oral Supplementation to Improve Short and Long-term Outcomes of Admitted Febrile Paediatric Patients With Biomarker-determined High-risk of Adverse Outcomes","Inclusion Criteria:\n\n* Enrolled in the initial prognostic screening component.\n* Sick children with fever (axillary temperature\\>37.5ºC) or a history of fever (within the preceding 72h) or with suspected severe disease.\n* 1m-\\\u003C60 months of age.\n* With an indication for admission, or having already been admitted to hospital due to their illness.\n* With an sTREM-1 PoC result classifying their disease as of \"moderate-high risk\" (\"yellow\" or \"red\") upon study recruitment and within D3.\n* Residents in the study area or willing to be contacted and traced during the study duration.\n* Willing to sign an informed consent document.\n* Willing to undergo and adhere to study procedures as explained in the IC document.\n\nExclusion Criteria:\n\n* Admission to hospital for social reasons (and not on account of their disease).\n* Children for which informed consent document has not been signed.\n* Known allergy or contraindication to any of the study supplements including lactose intolerance or observing a lactose-free diet.\n* Concurrent participation in any other clinical trial.\n* Patient under NPO or \"nothing by mouth\" prescription .\n* Contraindication for the insertion of a nasogastric tube (NGT) of for the enteral administration of drugs through the NGT in children who cannot tolerate by mouth.\n* Critically sick patient whose prognosis is considered by the clinical researcher as fatal outcome in the following hours after screening.\n* Any other condition determined by the investigators that makes it unlikely that the participant would complete the follow up until day 28 of study.","0 Months","60 Months",{"count":661,"type":22},2200,[61],"In low and middle-income countries, children admitted to hospital are not similarly ill, and do not all have a comparable prognosis. In fact, understanding at first encounter their risk of developing adverse outcomes (including mortality) could allow a more focused management and the tailoring of specific interventions to decrease in hospital mortality, and post discharge adverse longer-term outcomes. This clinical trial, part of the EChiLiBRiST larger project (\"Development and validation of a quantitative point-of-care test for the measurement of severity biomarkers to improve risk stratification of fever syndromes and enhance child survival\") has the two-fold objective of:\n\n1. Assessing whether a POINT-OF-CARE rapid triaging test (PoC RTT) based on the quantitative measurement at the bedside of the \"prognostic\" biomarker sTREM-1 (soluble-triggering receptor expressed on myeloid cells 1) can reliably identify those admitted children with a higher risk of adverse outcomes; and\n2. Assessing whether the therapeutic intervention (the L-arginine precursor, L-Citrulline, key in the nitric oxide biosynthesis), administered orally for 28 days to those children aged 1-\\\u003C60 months identified as \"moderate-to-high risk\" by the prognostic biomarker can improve outcomes as compared to those receiving an indistinguishable placebo.\n\nThis second objective will be assessed in a prospective multi-country, multi-site, individually randomised, two-arm, placebo-controlled, double blind clinical trial involving \\~888 children 1-\\\u003C60m of age admitted to hospital and determined to be at high risk of adverse outcomes by their baseline sTREM-1 levels. The trial will compare the efficacy of a twice-daily dose of L-citrulline syrup vs placebo (200-300mg\u002Fkg\u002Fday depending on weight-band; for 28 days) in reducing adverse outcomes in children with severe disease. The trial will be running independently but in parallel in two high-mortality settings in Mozambique and in Ethiopia.",[665,666,667],"Infectious Disease","Infections","Child, Only",{"date":645,"type":39},{"date":670,"type":39},"2025-12-08",{"date":672,"type":22},"2027-08-01",{"name":674,"class":46},"Barcelona Institute for Global Health",{"id":676,"slug":677,"hasResults":12,"nctId":678,"briefTitle":679,"officialTitle":680,"acronym":4,"eligibilityCriteria":681,"healthyVolunteers":12,"sex":18,"minAge":323,"maxAge":682,"enrollmentInfo":683,"targetDuration":4,"studyType":59,"phases":685,"briefSummary":686,"conditions":687,"keywords":689,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":696,"lastUpdatePostDateStruct":697,"startDateStruct":699,"completionDateStruct":700,"leadSponsor":702,"locationsCount":78},"100621987","adaptive-text-messaging-and-non-monetary-incentives-to-sustain-art-adherence-among-adolescents-living-with-hiv-in-ethiopia-100621987","NCT07377760","Adaptive Text Messaging and Non-Monetary Incentives to Sustain ART Adherence Among Adolescents Living With HIV in Ethiopia","Adaptive Text Messaging Reminders Combined With Non-monetary Incentives to Improve Adherence to Antiretroviral Treatment Among Adolescents Living With HIV in Ethiopia: a Hybrid Effectiveness-implementation Trial","Inclusion Criteria:\n\n* Consenting adolescents aged 15 to 19 who have been on ART for at least a year and want to continue treatment at the selected facility during the trial period are eligible.\n\nExclusion Criteria:\n\n* Participants outside of the specified age range.","19 Years",{"count":684,"type":22},327,[61],"Many adolescents living with HIV have difficulty taking their medicine on time, which can make it less effective and affect their health. This study will test whether sending reminder text messages, combined with small rewards like school supplies, hygiene kits, or sports items, can help adolescents take their HIV medicine regularly and stay in care. Each adolescent will choose a daily habit or routine to link to their medication. We will compare two groups receiving messages and rewards to a group receiving standard care to see which approach works best. We will also ask participants about their experience with the messages and rewards. The aim is to find a simple and effective way to help adolescents living with HIV stay healthy and in care.",[688],"Antiretroviral Therapy (ART) Adherence Among Adolescents Living With HIV",[690,691,692,693,694,695,94],"Adolescents with HIV","ART adherence","SMS reminders","habit-based digital intervention","cue-reward system","viral suppression","2026-01-22",{"date":698,"type":39},"2026-01-30",{"date":561,"type":22},{"date":701,"type":22},"2027-03-15",{"name":703,"class":46},"Arba Minch University",{"id":705,"slug":706,"hasResults":12,"nctId":707,"briefTitle":708,"officialTitle":709,"acronym":710,"eligibilityCriteria":711,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":712,"targetDuration":4,"studyType":59,"phases":714,"briefSummary":715,"conditions":716,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":721,"lastUpdatePostDateStruct":722,"startDateStruct":724,"completionDateStruct":726,"leadSponsor":728,"locationsCount":485},"100620998","effectiveness-of-family-integrated-newborn-care-to-improve-outcomes-for-preterm-and-low-birth-weight-neonates-100620998","NCT07364903","Effectiveness of Family-Integrated Newborn Care to Improve Outcomes for Preterm and Low-birth-weight Neonates","Effectiveness of Implementing Family-Integrated Newborn Care to Improve Outcomes for Preterm and Low-birth-weight Neonates in Resource-limited Settings; Quasi-experimental Design","FINC","Inclusion Criteria:\n\n* All neonates aged 0-28 days admitted to level-2 NCUs in the neonatal care unit, including Kangaroo Mother care ward or mothers' side ward, with conditions that require hospital stay at 48 hours; and\n* accompanied by at least one parent (preferably a mother) dedicated to spending up to 8 hours per day with the infant\n\nExclusion Criteria:\n\n* Neonates with major congenital anomalies\n* Infants with no family member to accompany the infant, or who do not consent to spend up to 8 hours per day in the NCU\n* Families with confirmed physical and\u002For mental problems limiting their capability to communicate and to engage, or those who leave against medical advice",{"count":713,"type":22},1020,[61],"The goal of this quasi-experimental study is to learn if integrating family in newborn care units as a key partner can improve the outcomes of preterm and low-birth-weight neonates. The main question\\[s\\] that the study aims to answer:\n\n• Does the implementation of the FINC intervention impact the neonatal outcomes for preterm and low-birth weight neonates in NCUs in resource-limited settings of Tigray, Northern Ethiopia? Researchers will compare the Length of hospital stay among preterm and low-birth-weight neonates admitted to hospitals included in the intervention groups and compared to the neonates admitted to hospitals in the control group.\n\nIn the intervention groups, family of preterm and low-birth-weight neonates will be trained, mentored, and integrated into the care targeted to their neonates.",[717,718,719,720],"Family Involvement\u002FEmpowerment","Family-centered Care","Intensive Care Units, Neonatal","Family Integrated Newborn Care","2026-01-18",{"date":723,"type":39},"2026-01-23",{"date":725,"type":39},"2025-12-16",{"date":727,"type":22},"2026-06-16",{"name":729,"class":46},"Laerdal Foundation",{"id":731,"slug":732,"hasResults":12,"nctId":733,"briefTitle":734,"officialTitle":735,"acronym":4,"eligibilityCriteria":736,"healthyVolunteers":12,"sex":55,"minAge":323,"maxAge":324,"enrollmentInfo":737,"targetDuration":4,"studyType":59,"phases":739,"briefSummary":740,"conditions":741,"keywords":4,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":744,"lastUpdatePostDateStruct":745,"startDateStruct":747,"completionDateStruct":749,"leadSponsor":751,"locationsCount":78},"100616105","trial-of-the-mittin-intervention-to-improve-contraceptive-side-effect-counseling-and-follow-up-in-ethiopia-100616105","NCT07301281","Trial of the \"Mittin\" Intervention to Improve Contraceptive Side Effect Counseling and Follow-up in Ethiopia","Cluster Randomized Controlled Trial of the \"Mittin\" Intervention in Addis Ababa, Ethiopia","Inclusion Criteria:\n\n* Woman\n* Started or continued using hormonal contraceptive method or copper IUD on day of recruitment\n* Ages 15-49 years\n* Willing to provide phone number and receive follow-up phone call\n\nExclusion Criteria:\n\n* Not planning to live in Addis Ababa for the next eight months\n* Can not verbally communicate\n* Not willing to provide consent for the study",{"count":738,"type":22},2715,[61],"The goal of this clinical trial is to learn if the \"Mittin\" intervention can improve women's ability to manage their fertility in line with their preferences among women aged 15-49 using hormonal contraceptives or intrauterine devices and attending public health centers in Addis Ababa, Ethiopia. The main question it aims to answer is: Does the Mittin intervention increase preference-aligned fertility management, contraceptive method satisfaction, and preferred contraceptive method use among participants compared to standard care?\n\nResearchers will compare women's outcomes in health centers providing the Mittin intervention to women's outcomes in health centers that offer standard care to see if Mittin improves women's ability to act in line with their contraceptive preferences.\n\nParticipants will\n\n* Receive either standard contraception services (control arm) or enhanced services (intervention arm)\n* Participate in a survey at the beginning of the study\n* Participate in surveys 4 and 8 months later",[742,743],"Contraception","Side Effects","2025-12-10",{"date":746,"type":39},"2025-12-24",{"date":748,"type":22},"2026-02",{"date":750,"type":22},"2027-06",{"name":284,"class":46},""]